Key result
Transcatheter aortic valve replacement using the Myval Octacor THV achieved a technical success rate of 98.8% in patients with severe aortic stenosis.
Why the study?
While the Myval balloon-expandable transcatheter heart valve (THV) has demonstrated safety and efficacy, clinical data on its latest iteration, the Octacor, remain limited.
Observational (n=252)
Yes
The next-generation Myval Octacor balloon-expandable THV demonstrated high technical success (98.8%) and favorable early clinical outcomes at 30 days in patients with severe aortic stenosis.
Answers are grounded in this paper and cite their sources.
May support Myval Octacor use in severe aortic stenosis; leaves open randomized comparisons for durability and outcomes.
BACKGROUND: THV is a standard treatment for elderly patients with severe AS, using either BE or self-expanding (SE) THVs. While the Myval BE THV has demonstrated safety and efficacy, data on its latest iteration, the Octacor, are limited. AIMS: To evaluate the clinical performance of the next-generation Myval Octacor balloon-expandable (BE) transcatheter heart valve (THV) in patients with severe, symptomatic native aortic valve stenosis (AS). METHODS: This observational, real-world, multicenter study involved patients deemed suitable for TAVR and treated with Octacor BE THV at 15 European centers. The primary endpoint was the rate of technical success (exit from procedure room) per VARC-3 criteria. Secondary endpoints included overall mortality, stroke, moderate-to-severe paravalvular leak (PVL), and need for permanent pacemaker (pPM) at 30-day and the longest available follow-up. An analysis by THV sizes (standard -20 to 29 mm vs. XL sizes -30.5 and 32 mm) was performed. RESULTS: From January to December 2023, 252 patients with severe AS underwent TAVR with the Octacor THV. The average age was 80.6 ± 6.7 years, and the mean STS score was 3.45%. Bicuspid anatomy was reported in 7.1% of cases (standard group 5.4% vs. XL group 20%, p = 0.004). Technical success was achieved in 98.8% of procedures (standard group 99.1% vs. XL group 96.7%, p = 0.2). At 30 days, overall mortality was 1.2%, stroke 3.2%, moderate-to-severe PVL 0.8%, and pPM 16.3%. CONCLUSIONS: The novel BE Myval Octacor THV showed high technical success and favorable early clinical outcomes. Longer follow-up and a head-to-head comparison versus other commercially available THVs are awaited.
No takes yet. Share an insight, caveat, or question.
Ielasi et al. (2025) conducted an observational in severe, symptomatic native aortic valve stenosis (AS) (n=252). Myval Octacor balloon-expandable transcatheter heart valve was evaluated on Rate of technical success (exit from procedure room) per VARC-3 criteria. Transcatheter aortic valve replacement using the Myval Octacor THV achieved a technical success rate of 98.8% in patients with severe aortic stenosis.
Synapse has enriched 10 related papers. Consider them for comparative context: